These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 12824790)

  • 1. Response to highly active antiretroviral therapy strongly predicts outcome in patients with AIDS-related lymphoma.
    Hoffmann C; Wolf E; Fätkenheuer G; Buhk T; Stoehr A; Plettenberg A; Stellbrink HJ; Jaeger H; Siebert U; Horst HA
    AIDS; 2003 Jul; 17(10):1521-9. PubMed ID: 12824790
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Survival is prolonged by highly active antiretroviral therapy in AIDS patients with primary central nervous system lymphoma.
    Skiest DJ; Crosby C
    AIDS; 2003 Aug; 17(12):1787-93. PubMed ID: 12891064
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Strong impact of highly active antiretroviral therapy on survival in patients with human immunodeficiency virus-associated Hodgkin's disease.
    Hoffmann C; Chow KU; Wolf E; Faetkenheuer G; Stellbrink HJ; van Lunzen J; Jaeger H; Stoehr A; Plettenberg A; Wasmuth JC; Rockstroh J; Mosthaf F; Horst HA; Brodt HR
    Br J Haematol; 2004 May; 125(4):455-62. PubMed ID: 15142115
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Changing incidence and prognostic factors of survival in AIDS-related non-Hodgkin's lymphoma in the era of highly active antiretroviral therapy (HAART).
    Wolf T; Brodt HR; Fichtlscherer S; Mantzsch K; Hoelzer D; Helm EB; Mitrou PS; Chow KU
    Leuk Lymphoma; 2005 Feb; 46(2):207-15. PubMed ID: 15621803
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Beneficial effect of highly active antiretroviral therapy on the prognosis of AIDS-related systemic non-Hodgkin lymphomas.
    Lascaux AS; Hemery F; Goujard C; Lesprit P; Delfraissy JF; Sobel A; Lepage E; Lévy Y
    AIDS Res Hum Retroviruses; 2005 Mar; 21(3):214-20. PubMed ID: 15795527
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of AIDS-related lymphomas: rituximab is beneficial even in severely immunosuppressed patients.
    Wyen C; Jensen B; Hentrich M; Siehl J; Sabranski M; Esser S; Gillor D; Müller M; Van Lunzen J; Wolf T; Bogner JR; Wasmuth JC; Christ H; Fätkenheuer G; Hoffmann C
    AIDS; 2012 Feb; 26(4):457-64. PubMed ID: 22112600
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Highly effective treatment of acquired immunodeficiency syndrome-related lymphoma with dose-adjusted EPOCH: impact of antiretroviral therapy suspension and tumor biology.
    Little RF; Pittaluga S; Grant N; Steinberg SM; Kavlick MF; Mitsuya H; Franchini G; Gutierrez M; Raffeld M; Jaffe ES; Shearer G; Yarchoan R; Wilson WH
    Blood; 2003 Jun; 101(12):4653-9. PubMed ID: 12609827
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognosis of AIDS-related systemic non-Hodgkin lymphoma treated with chemotherapy and highly active antiretroviral therapy depends exclusively on tumor-related factors.
    Miralles P; Berenguer J; Ribera JM; Rubio R; Mahillo B; Téllez MJ; Lacruz J; Valencia E; Santos J; Rodríguez-Arrondo F; Pintado V;
    J Acquir Immune Defic Syndr; 2007 Feb; 44(2):167-73. PubMed ID: 17117144
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of highly active antiretroviral therapy on survival among HIV-infected men with Kaposi sarcoma or non-Hodgkin lymphoma.
    Tam HK; Zhang ZF; Jacobson LP; Margolick JB; Chmiel JS; Rinaldo C; Detels R
    Int J Cancer; 2002 Apr; 98(6):916-22. PubMed ID: 11948473
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The prognostic importance of changes in CD4+ cell count and HIV-1 RNA level in women after initiating highly active antiretroviral therapy.
    Anastos K; Barrón Y; Cohen MH; Greenblatt RM; Minkoff H; Levine A; Young M; Gange SJ
    Ann Intern Med; 2004 Feb; 140(4):256-64. PubMed ID: 14970148
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A prognostic index for systemic AIDS-related non-Hodgkin lymphoma treated in the era of highly active antiretroviral therapy.
    Bower M; Gazzard B; Mandalia S; Newsom-Davis T; Thirlwell C; Dhillon T; Young AM; Powles T; Gaya A; Nelson M; Stebbing J
    Ann Intern Med; 2005 Aug; 143(4):265-73. PubMed ID: 16103470
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of combination chemotherapy and highly active antiretroviral therapy on immune parameters in HIV-1 associated lymphoma.
    Powles T; Imami N; Nelson M; Gazzard BG; Bower M
    AIDS; 2002 Mar; 16(4):531-6. PubMed ID: 11872995
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Highly active antiretroviral therapy (HAART) improves survival in HIV-associated Hodgkin's disease: results of a multicenter study.
    Hentrich M; Maretta L; Chow KU; Bogner JR; Schürmann D; Neuhoff P; Jäger H; Reichelt D; Vogel M; Ruhnke M; Oette M; Weiss R; Rockstroh J; Arasteh K; Mitrou P
    Ann Oncol; 2006 Jun; 17(6):914-9. PubMed ID: 16565210
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical and immunologic profile of AIDS-related lymphoma in the era of highly active antiretroviral therapy.
    Barclay LR; Buskin SE; Kahle EM; Aboulafia DM
    Clin Lymphoma Myeloma; 2007 Jan; 7(4):272-9. PubMed ID: 17324334
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Favorable impact of virological response to highly active antiretroviral therapy on survival in patients with AIDS-related lymphoma.
    Navarro JT; Ribera JM; Oriol A; Romeu J; Sirera G; Mate JL; Batlle M; Xicoy B; Grau J; Millá F; Feliu E
    Leuk Lymphoma; 2002 Sep; 43(9):1837-42. PubMed ID: 12685841
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hepatitis C and progression of HIV disease.
    Sulkowski MS; Moore RD; Mehta SH; Chaisson RE; Thomas DL
    JAMA; 2002 Jul; 288(2):199-206. PubMed ID: 12095384
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Changes in AIDS-related lymphoma since the era of highly active antiretroviral therapy.
    Besson C; Goubar A; Gabarre J; Rozenbaum W; Pialoux G; Châtelet FP; Katlama C; Charlotte F; Dupont B; Brousse N; Huerre M; Mikol J; Camparo P; Mokhtari K; Tulliez M; Salmon-Céron D; Boué F; Costagliola D; Raphaël M
    Blood; 2001 Oct; 98(8):2339-44. PubMed ID: 11588028
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Survival of AIDS patients with primary central nervous system lymphoma is dramatically improved by HAART-induced immune recovery.
    Hoffmann C; Tabrizian S; Wolf E; Eggers C; Stoehr A; Plettenberg A; Buhk T; Stellbrink HJ; Horst HA; Jäger H; Rosenkranz T
    AIDS; 2001 Nov; 15(16):2119-27. PubMed ID: 11684931
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association between Highly Active Antiretroviral Therapy and Type of Infectious Respiratory Disease and All-Cause In-Hospital Mortality in Patients with HIV/AIDS: A Case Series.
    Báez-Saldaña R; Villafuerte-García A; Cruz-Hervert P; Delgado-Sánchez G; Ferreyra-Reyes L; Ferreira-Guerrero E; Mongua-Rodríguez N; Montero-Campos R; Melchor-Romero A; García-García L
    PLoS One; 2015; 10(9):e0138115. PubMed ID: 26379281
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of the effectiveness of highly active antiretroviral therapy in persons with human immunodeficiency virus using biomarker-based equivalence of disease progression.
    Jacobson LP; Li R; Phair J; Margolick JB; Rinaldo CR; Detels R; Muñoz A
    Am J Epidemiol; 2002 Apr; 155(8):760-70. PubMed ID: 11943695
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.